(Q46743419)

24 December 2017

title

Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers (English)

1 reference

24 December 2017

author

Edward M. Sellers

6

1 reference

24 December 2017

author name string

S L McColl

1

1 reference

24 December 2017

A H Burstein

2

1 reference

24 December 2017

K R Reeves

3

1 reference

24 December 2017

C B Billing

4

1 reference

24 December 2017

M Stolar

5

1 reference

24 December 2017

language of work or name

English

0 references

publication date

20 February 2008

1 reference

24 December 2017

Clinical Pharmacology & Therapeutics

published in

1 reference

24 December 2017

volume

83

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

page(s)

607-614

1 reference

24 December 2017

Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Nicotine maintains robust self-administration in rats on a limited-access schedule

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Pharmacology of nicotine: addiction and therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Nicotine as a reinforcer in human subjects and laboratory animals.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Nicotine nasal spray and vapor inhaler: abuse liability assessment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Subjective effects of the nicotine lozenge: assessment of abuse liability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Assessment of dezocine for morphine-like subjective effects and miosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Guidelines and methodological reviews concerning drug abuse liability assessment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Alprazolam absorption kinetics affects abuse liability.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Abuse liability assessment of sibutramine, a novel weight control agent

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

A comparison of bupropion, dextroamphetamine, and placebo in mixed-substance abusers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Flavor improvement does not increase abuse liability of nicotine chewing gum.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Research design strategies to evaluate the impact of formulations on abuse liability

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Principles of initial experimental drug abuse liability assessment in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100510

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100510

1 reference

24 December 2017

1 reference

24 December 2017